Early Suppressive Effects of Chemotherapy on Recovery of Bone Marrow Megakaryocyte Precursors: Possible Relationship to Platelet Recovery
Open Access
- 1 January 1996
- journal article
- research article
- Published by Oxford University Press (OUP) in The International Journal of Cell Cloning
- Vol. 14 (S1) , 31-37
- https://doi.org/10.1002/stem.5530140704
Abstract
This study utilized a recently developed culture and quantitation system to detect megakaryocyte precursors in CD34+ bone marrow cells from normal donors and breast cancer patients treated with 5-fluorouracil, leucovorin, adriamycin and cyclophosphamide (FLAC). Bone marrow was obtained from patients before and then after their first cycle of FLAC once blood cell counts had recovered. CD34+ cells were isolated and placed in liquid culture with growth factors to stimulate proliferation and lineage commitment. Absorbance values from an enzyme-linked immunosorbent assay were used to quantitate expression of platelet glycoprotein GPIIb/IIIa. There was an increase in absorbance with increasing numbers of cells seeded per culture that was associated with an increase in the number of megakaryocyte lineage cells produced. After 10 days in liquid culture, absorbance values for expression of GPIIb/IIIa from 2,000 normal donor and pre-chemotherapy CD34+ marrow cells were ≥ 1.0. Absorbance values from cultures of post-chemotherapy CD34+ cells from four patients were similar to values from pre-chemotherapy CD34+ cells. In contrast, absorbance values from cultures of post-chemotherapy CD34+ cells from two other patients were low (absorbance + cells was reduced. Both of those patients developed prolonged thrombocytopenia and platelet nadirs of less than 20,000/μI during FLAC chemotherapy. In contrast, only one out of four patients whose cultures of post-chemotherapy CD34+ cells had absorbance values ≥ 1.0 developed platelet nadirs less than 20,000/μl. These results suggest that low platelet nadirs and delayed platelet recovery may be associated with suppressive effects of chemotherapy on recovery of megakaryocyte precursors.Keywords
This publication has 11 references indexed in Scilit:
- Comparative Effects of Insulin‐Like Growth Factor II (IGF‐II) and IGF‐II Mutants Specific for IGF‐II/CIM6‐P or IGF‐I Receptors on in Vitro HematopoiesisThe International Journal of Cell Cloning, 1996
- Prospective, randomized trial of 5-fluorouracil, leucovorin, doxorubicin, and cyclophosphamide chemotherapy in combination with the interleukin-3/granulocyte-macrophage colony-stimulating factor (GM-CSF) fusion protein (PIXY321) versus GM-CSF in patients with advanced breast cancerBlood, 1996
- CD34 + cell expansion and expression of lineage markers during liquid culture of human progenitor cellsThe International Journal of Cell Cloning, 1995
- A dose intensity study of FLAC (5-fluorouracil, leucovorin, doxorubicin, cyclophosphamide) chemotherapy and Escherichia coli-derived granulocyte-macrophage colony-stimulating factor (GM-CSF) in advanced breast cancer patientsAnnals of Oncology, 1994
- Platelet support and the use of cytokinesThe International Journal of Cell Cloning, 1994
- Abrogating chemotherapy-induced myelosuppression by recombinant granulocyte-macrophage colony-stimulating factor in patients with sarcoma: protection at the progenitor cell level.Journal of Clinical Oncology, 1992
- Treatment of chemotherapy-induced neutropenia by subcutaneously administered granulocyte colony-stimulating factor with optimization of dose and duration of therapy.Journal of Clinical Oncology, 1989
- A murine monoclonal antibody that completely blocks the binding of fibrinogen to platelets produces a thrombasthenic-like state in normal platelets and binds to glycoproteins IIb and/or IIIa.Journal of Clinical Investigation, 1983
- Effects of cyclophosphamide on murine bone marrow and splenic megakaryocyte‐CFC, granulocyte‐macrophage‐CFC, and peripheral blood cell levelsJournal of Cellular Physiology, 1982
- Autoimmune thrombocytopenic purpuraBlood, 1980